Astegolimab from Roche's Genentech fails phase 3 COPD trial, reflecting challenges in monoclonal antibody treatment for the ...

A new genetic test, based on data from more than five million people, can identify people at risk of severe obesity. The test can be performed on children before their genetic risk starts to shape ...

The biotech is planning to expand antisense oligonucleotide capabilities and infrastructure on campuses that already produce ...

The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly ...

CWM LLC has more than doubled its stake in Regeneron Pharmaceuticals, snapping up an additional 2,007 shares to now hold a ...